The Law of Demand is a bedrock theorem of economics. Increase the price of something and you get less of it. Decrease the price of something, you get more of it.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
Entrepreneur Scott Jones’ company, once an up-and-comer on the local tech scene, ceased operations Monday after recently becoming unable to service its debt.
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
Seriously, folks, you all need to take a step back from the hyperbole, the histrionics and the hyperventilating. It’s getting really old really quickly.
Jim Schellinger, a former Democratic candidate for governor, became president last year of the Indiana Economic Development Corp. In accepting the new position, he will retire from CSO Architects, where he had served as CEO, and sell his ownership stake.
Indianapolis-based tech entrepreneur Don Brown just ended his 22-year tenure with Interactive Intelligence Group, the company he sold for $1.4 billion only a week ago, but he’s already heavily involved in another venture.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
Kevin Patterson has stepped down at mid-season as general director of the struggling Indianapolis Opera and has quickly been replaced with a new leader.
Dr. Charles Thomas, who opened Chateau Thomas Winery on the south side of downtown Indianapolis in 1984 with his wife, is 84 years old and plans to retire.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Union workers and economists say pressuring individual factory owners won’t save U.S. manufacturing jobs lost to economic forces that are beyond the control of companies or the president.
